Arecor Therapeutics
Little Chesterford, United Kingdom

Arecor is a revenue-generating clinical-stage drug developer. Its proprietary Arestat formulation platforms are the basis of an in-house and partnered pipeline of enhanced products with lower development risks and less onerous regulatory approvals.

Investment Perspective

Arecor is exploiting its proprietary formulation expertise to create a portfolio of clinical assets. Drug agnostic technology partnerships with established global companies and internal work focused on Diabetes and Specialty Hospital Products are two sources of potential future licence deals. Arecor currently has four partnered products that will generate development and commercial milestones, plus royalties on sales. More significantly, select assets are in development in-house through to greater value-generation points, typically Phase II proof-of-concept, before out-licensing. Two projects, AT247 (ultra-rapid insulin) and AT278 (rapid ultra-concentrated insulin), are progressing through Phase I and show highly promising, differentiated profiles. The recent IPO raised £20m ensuring sufficient funding to achieve several material inflection points. We initiate coverage with a valuation of £103.7m, or 374p per share.

Market information

SymbolPrimary exchanges


AT278 Phase I delivers better than expected results
Lighthouse | 20 Sep 2021
Formulating the recipe for success
Initiation | 14 Sep 2021

Recent News

Positive results for AT278 Phase I trial
20 Sep 2021
FDA clearance of IND for AT247
14 Sep 2021
Exclusive formulation collaboration with Intas Pharmaceuticals
07 Sep 2021
Business update
14 Jul 2021